Buy
Original-Research: MPH Health Care AG - von First Berlin Equity Research GmbH
Einstufung von First Berlin Equity Research GmbH zu MPH Health Care AG
Unternehmen: MPH Health Care AG
ISIN: DE000A289V03
Anlass der Studie:
Empfehlung: Buy
seit: 04.10.2022
Kursziel: €58
Kursziel auf Sicht von: 12 Monate
Letzte Ratingänderung: -
Analyst: Ellis Acklin
First Berlin Equity Research hat ein Research Update zu MPH Health Care AG (ISIN: DE000A289V03) veröffentlicht. Analyst Ellis Acklin bestätigt seine BUY-Empfehlung und senkt das Kursziel von EUR 67,00 auf EUR 58,00.
Zusammenfassung:
Der Sechsmonatsbericht spiegelt die schlechte Kursentwicklung der beiden
börsennotierten Beteiligungen bis Ende Juni wider. Die Aktien der CR
Capital AG brachen in H1/22 um 10% ein, während die M1 Kliniken-Aktie rund
31% verlor. Dies führte zu einem Rückgang des NAVPS von MPH um 19% auf
€36,5 im ersten Halbjahr. Trotz der enttäuschenden Entwicklung der Aktien
haben sich die Geschäfte von M1 und CR Capital im bisherigen Jahresverlauf
gut entwickelt. M1 berichtete in H1 gute Behandlungszahlen, während CRC
gute H1-Ergebnisse meldete und die Aktionäre mit einer erhöhten
Dividendenausschüttung belohnte. Wir behalten unsere Kaufempfehlung bei,
senken aber unser Kursziel auf €58 (vorher: €67), um den aktualisierten
Bewertungsmodellen für M1 und CR Capital Rechnung zu tragen.
First Berlin Equity Research has published a research update on MPH Health Care AG (ISIN: DE000A289V03). Analyst Ellis Acklin reiterated his BUY rating and decreased the price target from EUR 67.00 to EUR 58.00.
Abstract:
Six month reporting reflected the poor share price performances of the two
listed holdings through the end of June. CR Capital AG shares slumped 10%,
while M1 Kliniken stock fell some 31% during H1/22. This triggered a 19% H1
decline in the MPH NAVPS to €36.5. Despite the disappointing stock
performances, operations at M1 and CR Capital have remained resilient YTD.
M1 reported good treatment numbers in H1, while CRC delivered strong H1
results and rewarded shareholders with an upped dividend payout. We
maintain our Buy rating but lower our TP to €58 (old: €67) to account for
updated valuation models for M1 and CR Capital.
Bezüglich der Pflichtangaben gem. §34b WpHG und des Haftungsausschlusses siehe die vollständige Analyse.
Die vollständige Analyse können Sie hier downloaden: http://www.more-ir.de/d/25555.pdf
Kontakt für Rückfragen
First Berlin Equity Research GmbH
Herr Gaurav Tiwari
Tel.: +49 (0)30 809 39 686
web: www.firstberlin.com
E-Mail: g.tiwari@firstberlin.com
-------------------übermittelt durch die EQS Group AG.-------------------
Für den Inhalt der Mitteilung bzw. Research ist alleine der Herausgeber bzw. Ersteller der Studie verantwortlich. Diese Meldung ist keine Anlageberatung oder Aufforderung zum Abschluss bestimmter Börsengeschäfte.
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.